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Pathophysiology 
•Bakken, 2009; Normal gut flora comprised of strict anaerobes such 
as: Peptostreptococcus, Prevotella, Ruminococcus, Bacteroides, 
Bifidobacterium, Eubacterium, and Lactobacillus.  
 
•Grehan et al., 2010; Individuals with C. difficile, aerobic and 
facultative anaerobic bacteria dominate the gut flora.  
 
•Borody et al., 2004; C. difficile not problematic until the beneficial 
gastrointestinal microbiota is depleted  
 
•Bakken, 2009; C. difficile has a spore-coat protecting the organism, 
it is relatively resistant to broad spectrum antibiotics, while the 
majority of the gut’s other beneficial microbiota is not. 
 
•Gough et al., 2011; CDIs recur in 35% of the patient population 
after treatment with antibiotic therapy, and 65% of these patients 
develop chronic re-manifestations of CDI.  
 
•Agito et al., 2013; Subsequent CDI rates double after two or more 
infections.  
 
 
FMT versus Vancomycin in treating recurrent CDI 
•Van Nood et al., 2013; First randomized clinical trial to pit FMT 
against vancomycin in the treatment of recurrent CDI 
 
•Gough et al., 2011; FMT was found to be safe and effective.  27 
case series with 317 patients were examined where vancomycin 
treatment had failed.  Disease resolution in 92% of cases after FMT. 
 
•Kassam et al., 2012; performed a systematic review and meta-
analysis which examined eleven studies with a total of 273 patients 
with recurrent CDI treated with FMT that had failed prior treatment 
with vancomycin.  Researchers found CDI resolution in 89.7% of 
patients involved in the study. 
 
 
Nasogastric tube (NGT) or Colonic administration of FMT 
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• Clostridium difficile infection (CDI) is the main cause of 
antibiotic-associated pseudomembranous colitis.   
 
• CDI has tripled over the last ten years due to the increased 
use of broad spectrum antibiotics. CDI has become 
increasingly difficult to manage with traditional therapies 
such as metronidazole and vancomycin due to mutations in 
the pathogen, resulting in resistant organisms.  
 
• The purpose of this review was to determine if fecal 
microbiota transplantation (FMT) is more effective in treating 
and curing CDIs than traditional vancomycin therapy. 
  
• The hypothesis was that FMT will have better treatment 
outcomes than traditional vancomycin therapy.   
 
• The findings indicated that FMT is a more cost effective, 
safer, and overall better treatment option for CDI than 
traditional therapies such as vancomycin.  
Statement of the Problem 
• CDI has become increasingly difficult to manage with traditional 
therapies such as metronidazole and vancomycin due to mutations 
in the pathogen resulting in resistant organisms.  
 
• These drug resistant pathogens have caused death, longer hospital 
stays, and increased nosocomial infections due to the highly 
infectious nature of the spore forming CDI pathogen. 
• The purpose of this review is to determine if fecal microbiota 
transplantation (FMT) is more effective in treating and curing 
Clostridium difficile infections (CDIs) than traditional 
vancomycin therapy.   
 
• The literature will examine research comparing treatment 
outcomes of FMT to vancomycin treatment in individuals with 
resistant CDI.   
 
• This information will enable one to compare treatment outcomes 
between the two therapies, as well as the best delivery method for 
FMT.  
1. In people with recurrent CDI, does FMT have better 
treatment outcomes and less recurrence of CDI episodes 
than traditional vancomycin therapy? 
 
2. Do people who undergo FMT have better success rates 
with nasogastric or colonic administration of FMT? 
• van Nood et al. (2013) randomized clinical trial comparing 
vancomycin and FMT effectiveness in the treatment of recurrent 
CDI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Gough et al., 2011; 27 case series and reports were examined with 
a total of 317 patients.  Patients had recurrent CDI not cured by 
multiple treatments with vancomycin.  89% cure rate of CDI after 
a single FMT treatment and 92% after a second treatment. Only 
5% of patients had CDI relapse. 
 
• Postigo and Kim, 2012; No statistical difference in the treatment 
efficacy between NG tube and colonoscopy guided FMT. All 
studies examined commented that FMT was a safe treatment 
option with relatively few adverse side effects. 
 
• Borody & Campbell, 2012; other possible clinical uses for FMT: 
crohns , ulcerative colitis, IBS, non-genetic autism, celiac . . . .  
• After reviewing the outcomes of FMT in the literature and 
examining CDI recurrence rates with currently suggested 
treatment protocols, I believe we are not using the best first-line 
treatment option for CDI cases.  FMT should be used as a first-
line treatment and not a last ditch effort.  Outcomes for FMT are 
better than vancomycin, as well as more durable.  
 
• Although more research is needed in these areas, FMT was also 
successfully utilized in the treatment of ulcerative colitis, IBS, 
and crohns.  Implications for FMT were directed at the treatment 
of celiac and other colonic infections and disturbances.  The 
primary obstacle keeping FMT from branching out as a treatment 
option in the afore mentioned areas is public acceptance of the 
therapy.  
 
• FMT has been partially accepted as a therapy for CDI only 
because the medical field is running out of good options to treat 
recurrent CDI.  The rising number of cases of vancomycin 
resistant enterococci (VRE) is forcing FMT to the front lines as a 
primary treatment option in these cases.  
 
• The medical field uses other bodily fluids on a daily basis for 
their beneficial attributes.  Fecal matter is no different.  Let’s not 
waste a valuable resource by flushing it away.  Save it for FMT! 
Aas, J., Gessert, C. E., & Bakken, J. S. (2003). Recurrent clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a 
 nasogastric tube. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 36(5), 580-585. 
 doi:10.1086/367657  
Agito, M. D., Atreja, A., & Rizk, M. K. (2013). Fecal microbiota transplantation for recurrent C difficile infection: Ready for prime time? Cleveland Clinic Journal 
 of Medicine, 80(2), 101-108. doi:10.3949/ccjm.80a.12110; 10.3949/ccjm.80a.12110  
Bakken, J. S. (2009). Fecal bacteriotherapy for recurrent clostridium difficile infection. Anaerobe, 15(6), 285-289. doi:10.1016/j.anaerobe.2009.09.007; 
 10.1016/j.anaerobe.2009.09.007  
Bardal, S., Waechter, J., & Martin, D. (2011). Infectious diseases. Applied pharmacology (1st ed., pp. 241). St, Louis, Missouri: Elsevier Saunders.  
Bartlett, J., Chang, T., & Gurwith, M. (1978). Antibiotic-associated pseudomembranous colitis due to toxin producing clostridia. New England Journal of 
 Medicine, (298), 531.  
Borody, T. J., & Campbell, J. (2012). Fecal microbiota transplantation: Techniques, applications, and issues. Journal of Clinical Gastroenterology, 41, 781-803.  
Borody, T. J., Warren, E. F., Leis, S. M., Surace, R., Ashman, O., & Siarakas, S. (2004). Bacteriotherapy using fecal flora: Toying with human motions. Journal of 
 Clinical Gastroenterology, 38(6), 475-483.  
Bowden, T. A.,Jr, Mansberger, A. R.,Jr, & Lykins, L. E. (1981). Pseudomembraneous enterocolitis: Mechanism for restoring floral homeostasis. The American 
 Surgeon, 47(4), 178-183.  
Eiseman, B., Silen, W., Bascom, G. S., & Kauvar, A. J. (1958). Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 44(5), 854-
 859.  
Gough, E., Shaikh, H., & Manges, A. R. (2011). Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile 
 infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 53(10), 994-1002. 
doi:10.1093/cid/cir632;  10.1093/cid/cir632  
Grehan, M. J., Borody, T. J., Leis, S. M., Campbell, J., Mitchell, H., & Wettstein, A. (2010). Durable alteration of the colonic microbiota by the administration of 
 donor fecal flora. Journal of Clinical Gastroenterology, 44(8), 551-561. doi:10.1097/MCG.0b013e3181e5d06b; 10.1097/MCG.0b013e3181e5d06b 
Guo, B., Harstall, C., Louie, T., Veldhuyzen van Zanten, S., & Dieleman, L. A. (2012). Systematic review: Faecal transplantation for the treatment of clostridium 
 difficile-associated disease. Alimentary Pharmacology & Therapeutics, 35(8), 865-875. doi:10.1111/j.1365-2036.2012.05033.x; 10.1111/j.1365-
 2036.2012.05033.x  
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013). Fecal microbiota transplantation for clsotridium difficile infection: Systematic review and meta-analysis. 
 American Journal of Gastroenterology, 108(April 2013), 500-508. doi:10.1038  
Kleger, A., Schnell, J., Essig, A., Wagner, M., Bommer, M., Seufferlein, T., & Harter, G. (2013). Fecal transplant in refractory clostridium difficile colitis. 
 Deutsches Arzteblatt International, 110(7), 108-115. doi:10.3238/arztebl.2013.0108; 10.3238/arztebl.2013.0108  
MacConnachie, A. A., Fox, R., Kennedy, D. R., & Seaton, R. A. (2009). Faecal transplant for recurrent clostridium difficile-associated diarrhoea: A UK case series. 
 QJM : Monthly Journal of the Association of Physicians, 102(11), 781-784. doi:10.1093/qjmed/hcp118; 10.1093/qjmed/hcp118  
Paasche, S. (2013). Fecal microbiota transplantation: An innovative approach to treating clostridium difficile disease. Journal of the American Academy of 
 Physician Assistants, 26(8), 46. doi:10.1097/01.JAA.0000432570.98817.16  
Postigo, R., & Kim, J. H. (2012). Colonoscopic versus nasogastric fecal transplantation for the treatment of clostridium difficile infection: A review and pooled 
 analysis.  Infection, 40, 643-48. 
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., . . . Keller, J. J. (2013). Duodenal infusion of donor feces for recurrent 
 clostridium difficile. The  New England Journal of Medicine, 368(5), 407-415. doi:10.1056/NEJMoa1205037; 10.1056/NEJMoa1205037  
Yoon, S. S., & Brandt, L. J. (2010). Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: A case series of 
 12 patients. Journal of Clinical Gastroenterology, 44(8), 562-566. doi:10.1097/MCG.0b013e3181dac035; 10.1097/MCG.0b013e3181dac035  
Table 2, Postigo & Kim  (2012): Outcomes of patients who underwent FMT via 
either  NGT or colonoscopy for recurrent  CDI treatment 
NGT group, 
n=34 
Colonoscopy group, 
n=148 
P-value 
Resolution after FMT 
(%) 
29  
(85.3) 
138  
(93.2) 
0.162 
No resolution after FMT 
(%) 
5 
(14.7) 
10 
(6.8) 
Relapse after FMT 
(%) 
2 
(5.9) 
8 
(5.4) 
1.000 
No relapse after FMT 
(%) 
32 
(94.1) 
140 
(94.6) 
Death due to CDI after 
FMT (%) 
0 
(0.0) 
4 
(2.7) 
1.000 
